|Videos|May 7, 2021
Dr. Alexander Kretschmer explains how the ExoDx Prostate test works
Author(s)Urology Times staff
The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.
Advertisement
Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
3
Pedro Freitas, MD, on consolidative surgery vs prolonged systemic therapy in MIBC
4
Treatment Selection in Advanced Prostate Cancer
5